{
    "clinical_study": {
        "@rank": "34955", 
        "arm_group": [
            {
                "arm_group_label": "betaxolol", 
                "arm_group_type": "Experimental", 
                "description": "betaxolol 0.25% 2 per day for 3 weeks"
            }, 
            {
                "arm_group_label": "placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "masked labeling also 2 per day administration"
            }
        ], 
        "brief_summary": {
            "textblock": "We hypothesize that topical betaxolol will reduce the development of severe retinopathy of\n      prematurity."
        }, 
        "brief_title": "Topical Betaxolol for the Prevention of Retinopathy of Prematurity", 
        "completion_date": {
            "#text": "November 2011", 
            "@type": "Actual"
        }, 
        "condition": "Development of Side Effects From Betaxolol", 
        "condition_browse": {
            "mesh_term": [
                "Retinal Diseases", 
                "Retinopathy of Prematurity"
            ]
        }, 
        "detailed_description": {
            "textblock": "The drug is administered twice a day between 32 and 35 weeks gestational age, at a t ime\n      when ROP is most likely to arise."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  <1251 grms birth weight\n\n        Exclusion Criteria:\n\n          -  ocular defect"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "32 Weeks", 
            "minimum_age": "32 Weeks"
        }, 
        "enrollment": {
            "#text": "23", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 6, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01660620", 
            "org_study_id": "108298"
        }, 
        "intervention": [
            {
                "arm_group_label": "betaxolol", 
                "intervention_name": "Betaxolol", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "placebo", 
                "description": "given topically", 
                "intervention_name": "topical betaxolol", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Betaxolol"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "betaxolol/ retinopathy of prematurity", 
        "lastchanged_date": "January 2, 2013", 
        "number_of_arms": "2", 
        "official_title": "Topical Betaxolol for the Prevention of Retinopathy of Prematurity", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "November 2011", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "babies were monitored and HR/RR monitored and recorded by masked observers, periodically", 
            "measure": "development of apnea and or bradycardia", 
            "safety_issue": "Yes", 
            "time_frame": "3 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01660620"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Smith-Kettlewell Eye Research Institute", 
            "investigator_full_name": "William V Good, MD", 
            "investigator_title": "Administrator", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Type I ROP was used as a secondary outcome measure", 
            "measure": "development of ROP requiring treatment", 
            "safety_issue": "No", 
            "time_frame": "7 weeks"
        }, 
        "source": "Smith-Kettlewell Eye Research Institute", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Ohio State University", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "University of Minnesota - Clinical and Translational Science Institute", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "University of Oklahoma", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "The University of Texas Health Science Center, Houston", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Smith-Kettlewell Eye Research Institute", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "August 2012"
    }
}